AR039662A1 - PREPARATIONS FOR TOPICAL ADMINISTRATION OF SUBSTANCES THAT HAVE ANTIANDROGEN ACTIVITY - Google Patents

PREPARATIONS FOR TOPICAL ADMINISTRATION OF SUBSTANCES THAT HAVE ANTIANDROGEN ACTIVITY

Info

Publication number
AR039662A1
AR039662A1 ARP030101423A ARP030101423A AR039662A1 AR 039662 A1 AR039662 A1 AR 039662A1 AR P030101423 A ARP030101423 A AR P030101423A AR P030101423 A ARP030101423 A AR P030101423A AR 039662 A1 AR039662 A1 AR 039662A1
Authority
AR
Argentina
Prior art keywords
preparations
substances
topical administration
compound
formula
Prior art date
Application number
ARP030101423A
Other languages
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR039662A1 publication Critical patent/AR039662A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparación que comprende al menos una forma e nanopartículas lípidas o una nanoemulsión que comprende al menos un compuesto de la fórmula (1), y / o una forma estereoisómera del compuesto de la fórmula (1) y / o una sal fisiológicamente tolerada del compuesto de la fórmula (1), en el que R1 es alquilo C5-17, o alquenilo C5-17, es adecuada para el tratamiento de la alopecia androgénica, del hirsutismo, es decir, impedir el crecimiento no deseado del cabello, y para el tratamiento de la seborrea y el acné y además se puede emplear en cosméticosA preparation comprising at least one form and lipid nanoparticles or a nanoemulsion comprising at least one compound of the formula (1), and / or a stereoisomeric form of the compound of the formula (1) and / or a physiologically tolerated salt of the compound of the formula (1), wherein R1 is C5-17 alkyl, or C5-17 alkenyl, is suitable for the treatment of androgenic alopecia, hirsutism, that is, preventing unwanted hair growth, and for seborrhea and acne treatment and can also be used in cosmetics

ARP030101423A 2002-04-27 2003-04-24 PREPARATIONS FOR TOPICAL ADMINISTRATION OF SUBSTANCES THAT HAVE ANTIANDROGEN ACTIVITY AR039662A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10218963A DE10218963A1 (en) 2002-04-27 2002-04-27 Preparations for the topical application of antiandrogen active substances

Publications (1)

Publication Number Publication Date
AR039662A1 true AR039662A1 (en) 2005-03-02

Family

ID=29264882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101423A AR039662A1 (en) 2002-04-27 2003-04-24 PREPARATIONS FOR TOPICAL ADMINISTRATION OF SUBSTANCES THAT HAVE ANTIANDROGEN ACTIVITY

Country Status (17)

Country Link
EP (1) EP1501806B1 (en)
JP (1) JP4633459B2 (en)
AR (1) AR039662A1 (en)
AT (1) ATE321756T1 (en)
AU (1) AU2003229658B2 (en)
BR (1) BRPI0309579B8 (en)
CA (1) CA2483786C (en)
DE (2) DE10218963A1 (en)
DK (1) DK1501806T3 (en)
ES (1) ES2256735T3 (en)
IL (1) IL164814A0 (en)
MX (1) MXPA04009571A (en)
MY (1) MY129714A (en)
PE (1) PE20031044A1 (en)
PT (1) PT1501806E (en)
TW (1) TWI285637B (en)
WO (1) WO2003093243A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
EP2299266A1 (en) 2003-12-19 2011-03-23 The Regents of the University of California Methods and materials for assessing prostate cancer therapies
CN100475781C (en) * 2004-02-13 2009-04-08 沃尼尔·朗伯有限责任公司 Androgen receptor modulators
CA2554696C (en) * 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
CA2570047C (en) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxy benzonitriles as androgen modulators
CN101044131A (en) * 2004-08-31 2007-09-26 沃尼尔·朗伯有限责任公司 Androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2656841T3 (en) 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
RU2449993C2 (en) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Diarylthiohydatoic compounds
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
RU2503446C2 (en) * 2012-02-07 2014-01-10 Алексей Валентинович Одинцов Hair growth product (versions) and methods of treating alopecia
KR20220025231A (en) 2012-09-26 2022-03-03 아라곤 파마슈티컬스, 인코포레이티드 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL222631B1 (en) * 2012-11-14 2016-08-31 Gdański Univ Medyczny Pharmaceutical composition comprising Roxithromycin, method for manufacture and medical use of the composition and the medicinal product comprising a composition
WO2014078929A1 (en) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Topical formulation for the prevention and treatment of alopecia and for inhibiting hair growth
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
CN103965112A (en) * 2014-05-13 2014-08-06 上海孚一生物科技有限公司 Compound with antiandrogen activity as well as preparation method and application of compound
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
KR20200070334A (en) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (en) * 1992-07-08 1994-09-02 Roussel Uclaf New substituted phenylimidazolidines, process for their preparation, their use as medicaments and the pharmaceutical compositions containing them.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2716110B1 (en) * 1994-02-16 1996-04-05 Roussel Uclaf Cosmetic or pharmaceutical compositions comprising liposomes.
AU726572B2 (en) * 1994-02-16 2000-11-09 Aventis Pharma S.A. Cosmetics or pharmaceutical compositions consisting of liposomes

Also Published As

Publication number Publication date
AU2003229658B2 (en) 2010-07-29
PT1501806E (en) 2006-06-30
DE10218963A1 (en) 2003-11-20
DE50302818D1 (en) 2006-05-18
CA2483786A1 (en) 2003-11-13
CA2483786C (en) 2011-08-09
ES2256735T3 (en) 2006-07-16
WO2003093243A1 (en) 2003-11-13
JP4633459B2 (en) 2011-02-16
BR0309579A (en) 2005-03-01
TW200407312A (en) 2004-05-16
DK1501806T3 (en) 2006-05-29
JP2005535584A (en) 2005-11-24
BR0309579B1 (en) 2014-10-07
ATE321756T1 (en) 2006-04-15
IL164814A0 (en) 2005-12-18
EP1501806B1 (en) 2006-03-29
PE20031044A1 (en) 2004-02-09
AU2003229658A1 (en) 2003-11-17
TWI285637B (en) 2007-08-21
BRPI0309579B8 (en) 2021-05-25
MXPA04009571A (en) 2005-01-11
EP1501806A1 (en) 2005-02-02
MY129714A (en) 2007-04-30

Similar Documents

Publication Publication Date Title
AR039662A1 (en) PREPARATIONS FOR TOPICAL ADMINISTRATION OF SUBSTANCES THAT HAVE ANTIANDROGEN ACTIVITY
JP4152987B2 (en) Regulation of mammalian hair growth
US8632759B2 (en) Hair restorer
AU646069B2 (en) Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
US20090214628A1 (en) Methods and compositions for treatment of skin
ATE281143T1 (en) USE OF A COMBINATION OF ACTIVE INGREDIENTS CONTAINING BIOQUINONES FOR THE PRODUCTION OF COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND PROPHYLAXIS OF DANDRUFF
EP1948236A2 (en) Methods and compositions for treatment of skin
PT1123082E (en) PREPARATIONS FOR APPLICATION TOPIC OF SUBSTANCES OF ANTI-ANDORGANIC ACTIVITY
WO2015157771A1 (en) Hair enhancing formulation
ES2485391T3 (en) Use of coumarin, butylated hydroxyanisole and ethoxyquin for the treatment of gray hair
JPS61183206A (en) Cell-activating agent
KR930703252A (en) Use of coucurbitin used in the manufacture of anti-allergic cosmetics or pharmaceutical, especially dermatological compositions, and methods of using the same
US20120258972A1 (en) Composition and Methods for Treating Hair Loss
EA032573B1 (en) Skin lightening composition comprising 4-hexylresorcinol and ilomastat
Desai et al. Cysteamine: Clinical efficacy, safety and tolerability versus best-in-class treatments for melasma
Mashhood Treatment of hyperpigmentation disorders
KR102611504B1 (en) Composition for promoting the hair growth comprising kirenol
BR112017013142B1 (en) DERMATOLOGICAL AND/OR COSMETIC PREPARATION, USE OF A DERMATOLOGICAL AND/OR COSMETIC PREPARATION AND PROCESS FOR THE PRODUCTION OF A DERMATOLOGICAL AND/OR COSMETIC PREPARATION
JPWO2013180229A1 (en) Hair growth composition
ITMI942645A1 (en) USE OF GUANIDIN-IMIDAZOLIC DERIVATIVES TO HELP THE STIMULATION OF HAIR GROWTH.
JPH11279032A (en) Antidandruff agent composition
WO2003075882A2 (en) Method of depigmenting skin and hairs
JPH11322546A (en) Cosmetic for scalp and hair
JPS62265213A (en) Hair tonic
JP2001302494A (en) Composition including retinoid for skin care and caffeine

Legal Events

Date Code Title Description
FG Grant, registration